Journal of Antimicrobial Chemotherapy (2000) 46, 501-508
© 2000 The British Society for Antimicrobial Chemotherapy
Antimicrobial practice |
Appropriate use of restricted antimicrobial agents in hospitals: the importance of empirical therapy and assisted re-evaluation
a Medical Intensive Care, b Hospital Pharmacy, c Clinical Microbiology Laboratory and d Infection Control Unit, Hôpital Henri Mondor, Créteil, France
Abstract
We evaluated the appropriateness of use of restricted antimicrobial agents in the context of a newly implemented order form and delivery system for restricted antimicrobial agents, using sequential prospective audits of prescriptions. Four antimicrobial agents were selected: glycopeptides (61 prescriptions), ciprofloxacin (42), piperacillintazobactam (42) and imipenem cilastatin (47). The justification and adequacy of the antibiotic or combination used, reassessment of therapy and duration of treatment were appraised with reference to the clinical situation and hospital's guidelines. Of the 192 prescriptions, 30 (16%) were empirical therapy, 95 (49%) empirical and secondarily documented and 67 (35%) initially documented therapy. Overall, 73% of prescriptions conformed to guidelines, but the adequacy varied from 93% for vancomycin to only 38% for ciprofloxacin. Of 83/157 initially inadequate prescriptions, 42 (51%) were switched according to guidelines, but only 14% of ciprofloxacin prescriptions were adapted later. An intervention audit with counselling on ciprofloxacin usage increased this rate to 75%. Although implementation of the guidelines resulted in a marked reduction in overall antimicrobial costs, inappropriate antibiotic usage may persist for some drugs despite restricted access. These results emphasize the need for combined interventions using education and expert counselling, targeted to classes of antibiotic for which inappropriate usage is most common.
Notes
* Corresponding author. Unité d'Hygiène et Prévention de l'Infection et Service de Réanimation Médicale, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, 51 Avenue Maréchal de Lattre de Tassigny, 94010 Créteil, France. Tel: +33-1-4981-2394; Fax: +33-1-4207-9943; E-mail: christian.brun-buisson{at}hmn.ap-hop-paris.fr
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
H. Ding, Y. Yang, Q. Lu, Y. Wang, Y. Chen, L. Deng, A. Wang, Q. Deng, H. Zhang, C. Wang, et al. Five-year Surveillance of Antimicrobial use in Chinese Pediatric Intensive Care Units J Trop Pediatr, August 1, 2008; 54(4): 238 - 242. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-R. Zahar, C. Rioux, E. Girou, A. Hulin, C. Sauve, A. Bernier-Combes, C. Brun-Buisson, and P. Lesprit Inappropriate prescribing of aminoglycosides: risk factors and impact of an antibiotic control team J. Antimicrob. Chemother., September 1, 2006; 58(3): 651 - 656. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Raveh, E. Muallem-Zilcha, A. Greenberg, Y. Wiener-Well, Y. Schlesinger, and A.M. Yinnon Prospective drug utilization evaluation of three broad-spectrum antimicrobials: cefepime, piperacillin-tazobactam and meropenem QJM, June 1, 2006; 99(6): 397 - 406. [Abstract] [Full Text] [PDF] |
||||


